Generate Biomedicines (NASDAQ:GENB) Sees Strong Trading Volume – What’s Next?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) saw unusually-strong trading volume on Thursday . Approximately 355,208 shares changed hands during mid-day trading, a decline of 34% from the previous session’s volume of 541,570 shares.The stock last traded at $14.8650 and had previously closed at $12.91.

Wall Street Analyst Weigh In

GENB has been the topic of several recent research reports. Morgan Stanley upped their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Guggenheim assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Price Performance

The company has a 50-day simple moving average of $13.12.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.